Navigation Links
CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G

stance and the improved patient comfort due to lower PONV supports CeNeS justification of a substantial price premium for M6G compared to morphine.

We are actively pursuing potential partners for M6G and are confident that agreements can be reached. We are well positioned to deliver significant value to shareholders by the successful commercialisation of M6G".

- END -

CeNeS Pharmaceuticals plc will be announcing its preliminary results for the year ended 31 December 2006 on Wednesday 28 March 2007. On the same day the Company will be hosting an R&D presentation at the offices of Financial Dynamics. The presentation will start at 9:30am and is expected to conclude at 11am.

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com

About M6G Morphine formulations are the gold standard treatment for the relief of moderate to severe post-operative pain. A limitation of morphine treatment is often the unpleasant side effects experienced, of which nausea and vomiting are the most common. PONV is rated among patients as one of the most distressing after-effects of surgery and reduces their quality of life.

The active potent metabolite of morphine, morphine-6-glucuronide (M6G), may offer therapeutic advantages over morphine in having an equivalent analgesic effect, but with a reduced tendency to cause nausea, vomiting and respiratory depression. Phase II and III clinical trials have sho
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:7/24/2014)... -- Delivery of the Report will take 2-3 ... Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... on Global and Chinese Hemodialysis Machine industry. The ... Machine including its classification, application and manufacturing technology. ... manufacturers of Hemodialysis Machine listing their product specification, ...
(Date:7/24/2014)... 24, 2014 Cancer patients in the west of ... cancer treatment closer to home when a new radiotherapy center ... Medical Systems (NYSE: VAR ) has been selected ... in June for four TrueBeam™ medical linear accelerators. ... and efficient radiotherapy and radiosurgery treatments, will replace older treatment ...
(Date:7/24/2014)...  Blueprint Medicines (Blueprint), a leader in discovering highly ... announced the appointment of Jeffrey Albers as ... Algeta ASA, where he served on the executive management ... Bayer. Mr. Albers succeeds Alexis Borisy , co-founder ... Rock Ventures, who will remain an active member of ...
Breaking Medicine Technology:Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer 2
... Nov. 14, 2011 Tengion, Inc. (Nasdaq: ... of a restructuring plan, and reported its financial results ... restructuring plan is designed to fund the Company,s lead ... the Company,s anticipated cash utilization.  As a result of ...
... Texas, Nov. 14, 2011 Novation commends the IMS ... raising awareness of the drug shortage crisis facing America,s ... Look at Products, Suppliers and Volume Volatility."   ... 2011 Executive Order, is helping bring much-needed attention to ...
Cached Medicine Technology:Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 2Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 3Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 4Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 5Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 6Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 7Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 8Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 9Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 10Novation Applauds the IMS Institute for Healthcare Informatics for Calling Attention to the Drug Shortage Crisis Facing American Hospitals 2Novation Applauds the IMS Institute for Healthcare Informatics for Calling Attention to the Drug Shortage Crisis Facing American Hospitals 3
(Date:7/24/2014)... women who received the Human Papillomavirus Vaccination (HPV) ... of abnormal Pap test results than those who ... journal Sexually Transmitted Diseases . , ... and School of Medicine conducted a cross-sectional study ... routine cervical cytology testing. HPV status and demographic ...
(Date:7/24/2014)... According to market research report "3D Mapping Market: ... Analysis - 2018", the 3D mapping and 3D ... by 2018 at a CAGR of 47.9% by ... and 30 figures spread through 222 pages and ... Business Models, Technology Roadmap, Forecasts and Analysis - ...
(Date:7/24/2014)... York (PRWEB) July 24, 2014 ... ( http://www.drugbot.com/testosterone/lawsuit/ ) against the manufacturer of Delatestryl, ... risks associated with the low testosterone injection, Bernstein ... was filed in the Ontario Superior Court of ... use of low testosterone therapy is associated with ...
(Date:7/24/2014)... 24, 2014 (HealthDay News) -- Giving low-income families vouchers ... increase their consumption of these healthy foods, according to ... fewer fruits and vegetables. In addition to not having ... issue. Farmers, market vouchers could help address both of ... healthy food options, farmers, market incentives may be able ...
(Date:7/24/2014)... new formulation of a powerful narcotic painkiller that discourages ... been approved by the U.S. Food and Drug Administration. ... the pill is a combination of the narcotic oxycodone ... of oxycodone. The naloxone is only activated when the ... the FDA. While Targiniq has only been approved ...
Breaking Medicine News(10 mins):Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 3Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 4Health News:Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports 3Health News:Farmers' Market Vouchers May Help Poorer Families Eat Healthier 2Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2
... GenPrime, Inc. a leading,provider of rapid microbial analysis ... Contamination Test for Platelets(TM). The,test is a rapid ... and,anaerobic bacteria commonly found in contaminated platelets. The ... pre-market notification with the Food,and Drug Administration (FDA). ...
... ago, deconstructing and analyzing DNA codes took scientists several years ... floor of a building. Now, a genetic sequencer the ... a couple of days. , Thanks to a ... of Houstons Institute for Molecular Design (IMD), researchers will be ...
... example of the Bush Administration promoting, politics over a sound health ... oversight of the federal family planning program and the health of ... ... National Abortion,Federation (NAF) denounces the appointment of Dr. Susan Orr as ...
... Next Big Challenge, WASHINGTON, Oct. 17 Is ... drugs,and devices to physicians and the public?, That,s ... and debate at a,landmark Colloquium, Communicating Risk/Safety Information: How ... Drug Law Institute (FDLI),Dec. 6, 2007, in Washington, D.C., ...
... Oct. 17 40|86 Strategic Income,Fund (NYSE: CFD ... 9, 2007 to holders of record at the close ... Fund is a closed-end investment management,company. The Fund,s primary ... in the Fund,s prospectus, the Fund intends to,distribute substantially ...
... Care, Inc. (NYSE:,HCR) announced that at its special ... merger agreement providing for the,merger of Manor Care, ... 99 percent of the shares present and voting ... number of shares voting to approve,the merger agreement ...
Cached Medicine News:Health News:GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets 2Health News:Half-million-dollar DNA sequencer to boost genetic science research at UH 2Health News:National Abortion Federation Denounces the Appointment of Dr. Orr to Oversee Federal Family Planning Funds 2Health News:Food and Drug Law Institute Sponsors Colloquium on Communicating Risk/Safety Drug Information 2
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The XT-2000i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The XE-2100L automated hematology analyzer features new hematology parameters as NRBC, IRF, and HPC that offer valuable and accurate clinical information....
The XE-2100 automated hematology analyzer features new hematology parameters as NRBC, IRF, and HPC that offer valuable and accurate clinical information....
Medicine Products: